ST. LOUIS, Oct. 25, 2013 /PRNewswire-iReach/ -- Lee Biosolutions, is a manufacturer and producer of high purity proteins announces a major scientific breakthrough. The St. Louis-based biotechnology firm recently developed a proprietary process to effectively and efficiently purify and stabilize two important gastric cancer protein biomarkers. As a result, they are producing Pepsinogen I and Pepsinogen II, critical components in serum pepsinogen tests that will revolutionize early detection of stomach and gastric cancer.
According to American Association for Cancer Research (AACR), stomach cancer is the second-leading cause of cancer-related deaths worldwide and the top cause in Eastern Asia, which comprises China, Japan, Taiwan and Korea. Studies have shown that if the disease is detected early, patients five-year survival rates increases by 90 percent. Asian and European governments have been advocating mass screenings for decades, but traditional upper endoscopy procedures are painful, invasive and expensive. Lee Biosolutions proteins Pepsinogen I and Pepsinogen II production capabilities enables international diagnostics companies to quickly manufacture serum pepsinogen tests, which are affordable and easy to administer. Lee has scaled up production to meet global market demand.
"Gastric cancer screening involves H Pylori infection detection, measurement of serum pepsinogen I and II and possibly enodoscopic examination," said Burton Lee, president of Lee Biosolutions. "The challenge to-date for diagnostic companies has been producing tests efficiently and affordably. Recently, Lee Biosolutions research and development team cracked the code for purifying and stabilizing two very important gastric and stomach cancer protein biomarkers, Pepsinogen I and Pepsinogen II, primary components in serum pepsinogen tests. We now have the expertise, processes and manufacturing capacity to produce enough of these biomarkers to make a significant impact."
Serum pepsinogen tests for gastric cancer enable healthcare providers to identify high risk patients for further monitoring. Not only do the tests increase survival rates by 90 percent but they also decrease the cost of mass screening programs. LeeBio currently has clients in Eastern Asia and Europe that plan to produce, distribute and administer the tests.
About Lee Biosolutions, Inc.
Lee Biosolutions is an international producer of high purity human, animal and recombinant proteins, biological fluids, biochemicals, antibodies and immunoreagents. Headquartered in St. Louis and founded in 1975, the biotechnology firm serves academic and scientific researchers as well as IVD manufacturers worldwide. Lee Biosolutions produces and processes the raw biomaterials used in drug discovery and development, laboratory equipment calibration, clinical diagnosis and product testing. These include human neutrophil elastase, human myeloperoxidase isoform c, alpha fetoprotein, beta 2 microglobulin, and amylase. The company is ISO 9001:2008 certified, FDA registered and meets USDA guidelines. To learn more about Lee Biosolutions visit www.LeeBio.com
Media Contact: Burton Lee, Lee Biosolutions, Inc, 314-968-1091, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Lee Biosolutions, Inc